Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL

View Full Paper
Ask AI
Bookmark
Share

Authors

SASairah AhmedJRJuan Luis RegueraHGHervé Ghesquières

Discussion

Loading...

Member takes

Overview

Observational analysis shows high response rates of 97% in patients with 3L+ follicular lymphoma, indicating liso-cel's durable efficacy and safety.

Key Points

  • High response rates were noted with liso-cel therapy, with an overall response rate of 97% in 3L+ follicular lymphoma patients.
  • The study reported durable responses and high 3-year survival rates, suggesting long-term benefits of liso-cel treatment.
  • Analysis included evaluation of hypogammaglobulinemia and cytokine release syndrome events over time, confirming a favorable safety profile.
  • Results highlight the safety and efficacy of liso-cel, indicating its potential as a treatment option for patients with refractory conditions.

Cite This Study

Ahmed et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4bchttps://doi.org/10.1182/blood-2025-467
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Patient-reported outcomes (PROs) with lisocabtagene maraleucel (liso-cel) in patients with third line or later (3L+) R/R MZL from the Phase 2 TRANSCEND FL study2025 · 1 citations
  2. 2Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM2025 · 1 citations
  3. 3Five-year survival outcomes from TRANSCEND NHL 001 of lisocabtagene maraleucel in R/R LBCL2026 · 1 citations
  4. 4Efficacy and safety of lisocabtagene maraleucel monotherapy in relapsed or refractory large B-cell lymphoma: A systematic review and meta-analysis of clinical trials and real-world studies2025 · 1 citations
  5. 5Outpatient (OP) use of lisocabtagene maraleucel (liso-cel) in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): Real-world data from the CIBMTR registry2025